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Abstract
Background: Although clinical diabetes mellitus is obviously a high risk factor for myocardial infarction (MI), in
experimental studies disagreement exists about the sensitivity to ischemic injury of an infarcted myocardium.
Recently, our group demonstrated that diabetic animals presented better cardiac function recovery and cellular
resistance to ischemic injury than nondiabetics. In the present study, we evaluated the chronic effects of MI on left
ventricular (LV) and autonomic functions in streptozotocin (STZ) diabetic rats.
Methods: Male Wistar rats were divided into 4 groups: control (C, n = 15), diabetes (D, n = 16), MI (I, n = 21), and
diabetes + MI (DI, n = 30). MI was induced 15 days after diabetes (STZ) induction. Ninety days after MI, LV and
autonomic functions were evaluated (8 animals each group). Left ventricular homogenates were analyzed by
Western blotting to evaluate the expression of calcium handling proteins.
Results: MI area was similar in infarcted groups (~43%). Ejection fraction and +dP/dt were reduced in I compared
with DI. End-diastolic pressure was additionally increased in I compared with DI. Compared with DI, I had increased
Na
+-Ca
2+ exchange and phospholamban expression (164%) and decreased phosphorylated phospholamban at
serine
16 (65%) and threonine
17 (70%) expression. Nevertheless, diabetic groups had greater autonomic dysfunction,
observed by baroreflex sensitivity and pulse interval variability reductions. Consequently, the mortality rate was
increased in DI compared with I, D, and C groups.
Conclusions: LV dysfunction in diabetic animals was attenuated after 90 days of myocardial infarction and was
associated with a better profile of calcium handling proteins. However, this positive adaptation was not able to
reduce the mortality rate of DI animals, suggesting that autonomic dysfunction is associated with increased
mortality in this group. Therefore, it is possible that the better cardiac function has been transitory, and the
autonomic dysfunction, more prominent in diabetic group, may lead, in the future, to the cardiovascular damage.
Introduction
Diabetes has been associated with an increased risk of
cardiovascular abnormalities and microvascular compli-
cations. Although microvascular retinopathy and nephro-
pathy are associated with a high degree of morbidity, the
increased mortality in patients with diabetes is primarily
a consequence of cardiovascular disease [1]. In fact, clini-
cal studies have demonstrated that diabetes, with conse-
quent cardiomyopathy and cardiovascular neuropathy, is
an independent risk factor for cardiovascular disease and
is associated with a 2- to 4-fold increased risk of coronary
heart disease [2].
In this regard, experimental data have demonstrated
that hyperglycemia in diabetic animals leads to changes
in the heart that contribute to injury during and follow-
ing an ischemic event; however, the response of an
uncontrolled hyperglycemic diabetic heart to ischemic
injury remains controversial [3-5]. Experimental studies
[6-8] using an ischemia/reperfusion protocol have shown
that hearts from streptozotocin (STZ) diabetic rats that
undergo a period of no-flow ischemia have a reduced
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function significantly better than nondiabetic hearts, indi-
cating a possible cardioprotective role of hyperglycemia.
In fact, the exposure to short periods of abnormally
higher glucose medium or diabetes has been found to
protect the heart against a variety of pathological insults,
including ischemia, hypoxia, and calcium overload [9,10].
However, most studies reported in the literature have
been conducted using an ischemia/reperfusion model,
thus it has not been possible to verify whether chronic
hyperglycemia can protect the diabetic heart against
permanent coronary ligation. Recently, our group demon-
s t r a t e dt h a ta f t e r1 5d a y so fM I ,d i a b e t i ca n i m a l sh a d
reduced heart fibrosis, improved systolic function, and
reduced infarct size. In accordance with this study, it is
possible that these data may have indicated the final path-
way promoted by a positive balance in regulatory genes
related to programmed cell survival, reduced inflammatory
cytokines, and increased utilization of glucose as an energy
substrate [9]. However, other important risk factors, such
as cardiovascular autonomic neuropathy, and influences
on the mortality rate were not evaluated in this study.
Changes in critical processes that regulate intracellular
calcium concentration and signaling have been a hall-
mark of cardiomyopathy and heart failure. Alterations in
the expression and activity of cardiac proteins that parti-
cipate in the calcium handling, (e.g., calcium pump
ATPase of sarcoplasmic reticulum (SERCA2), depho-
sphorylated phospholamban (PLN), which respectively
decreases the affinity of SERCA2 for calcium, and sarco-
lemmal sodium calcium exchanger (NCX), which med-
iates calcium efflux from the cell [11] have been shown
to occur in cardiomyopathy of STZ diabetic rats [12] and
after MI [13]. However, the impact of association
between STZ diabetes and MI in the expression of cal-
cium handling proteins remains unknown. In this sense,
the aim of the present study was to investigate the effects
of hyperglycemia induced by STZ diabetes in left ventri-
cular (LV) dysfunction, net balance of regulatory proteins
involved in intracellular calcium homeostasis, autonomic
dysfunction and mortality rate, in rats that underwent
90 days of MI.
Methods
Animals and Groups
Experiments were performed in adult male Wistar rats
(~240 g) from the Animal House of the University of São
Paulo, São Paulo, Brazil. Rats were fed standard laboratory
chow and water ad libitum. The animals were housed in
collective polycarbonate cages in a temperature-controlled
room (22°C) with a 12-hour dark-light cycle (light 07:00-
19:00 h). The experimental protocol was approved by
the institutional animal care and use committee of the
Medical School of the University of São Paulo, and this
investigation was conducted in accordance with the pre-
viously described [14]. Rats were randomly assigned to
control (C, n = 15), diabetes (D, n = 16), myocardial
infarction (I, n = 21), and diabetes + myocardial infarction
(DI, n = 30).
Diabetes Induction
Experimental diabetes was induced by intravenous injec-
tion of 50 mg/kg STZ (Sigma Chemical Co., St. Louis,
MO) dissolved in citrate buffer (pH 4.2). Rats were
fasted overnight before STZ injection. Control rats were
injected with buffer only (10 mM citrate buffer, pH 4.5).
Forty-eight hours after STZ injection, diabetes was con-
firmed by blood glucose levels above 200 mg/dL.
Myocardial Infarction
Fifteen days after diabetes induction or buffer injection,
anesthetized rats (80 mg/kg Ketamine and 12 mg/kg Xyla-
zine, i.p.) underwent surgical occlusion of the left coronary
artery, which resulted in myocardial infarction, as pre-
viously described elsewhere [9,13]. Briefly, a left intercostal
thoracotomy was performed, the third intercostal space
dissected, and the heart exposed. The left anterior des-
cending coronary artery was occluded with a single nylon
(6.0) suture at approximately 1 mm distal to the left atrial
appendage. The chest was closed with silk suture.
The animals were maintained in the ventilator until
recovery. All rats received antibiotics (penicillin, 20,000 U)
and Tramadol (20 mg/kg, every 6 h). Eight animals from
each group were evaluated 90 days after myocardial infarc-
tion induction (105 days after diabetes induction) to per-
form the following experimental protocols. The whole
sample (n = 75) was evaluated for mortality, an assessment
that started after myocardial infarction surgery, excluding
the influence of anesthesia or surgical procedure stress.
Noninvasive Evaluation of Left Ventricular Function:
Echocardiographic Measurements
Echocardiography was performed by a double-blinded
observer, under the guidelines of the American Society
of Echocardiography, 2 days (initial evaluation) and
90 days (final evaluation) after myocardial infarction.
Rats were anesthetized (80 mg/kg Ketamine and
12 mg/kg Xylazine), and images were obtained with a
10-14 mHz linear transducer in a SEQUOIA 512
(ACUSON Corporation, Mountain View, CA) for mea-
surements of morphometric parameters: left ventricular
(LV) mass (corrected by body weight) and LV end-
diastolic diameter (LVEDD); systolic function para-
meters: ejection fraction (EF) and velocity of circum-
ferential fiber shortening (VCF); diastolic function
parameters: LV isovolumetric relaxation time (IVRT)
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square root of R-R interval, because EDT and IVRT
are HR dependent; and global function: myocardial
performance index (MPI). Echocardiographic para-
meters were measured as described in detail elsewhere
[9,13].
The infarction area was delimited, which led us to
analyze the movement of the LV walls. Regions with
systolic shortening classified as absent or with paradoxi-
cal movement were considered infarcted. The infarcted
area (in %) was thus measured as the ratio of these
regions by the total area of LV walls [9,13,15].
Autonomic Evaluations
One day after the final echocardiographic evaluation, 2
catheters filled with 0.06 mL of saline were implanted into
the femoral artery and femoral vein of the anesthetized
rats (80 mg/kg Ketamine and 12 mg/kg Xylazine, IP).
Twenty-four hours later, the arterial cannula was con-
nected to a strain-gauge transducer (Blood Pressure
XDCR, Kent Scientific, USA), and arterial pressure (AP)
signals were recorded over a 30-minute period in con-
scious animals by a microcomputer equipped with an ana-
log-to-digital converter board (WinDaq, 2-kHz, DATAQ,
Springfield, OH). The recorded data were analyzed on a
beat-to-beat basis to quantify changes in mean AP (MAP)
and heart rate (HR) [13,15].
Sequential bolus injections (0.1 mL) of increasing doses
of phenylephrine (0.25 to 32 μg/kg) and sodium nitro-
prusside (0.05 to 1.6 μg/kg) were given to induce
increases or decreases in MAP pressure responses (for
each drug), ranging from 5 to 40 mm Hg. Baroreflex sen-
sitivity expressed as bradycardic (BR) and tachycardic
(TR) responses in beats per minute per millimeter of
mercury, as described elsewhere. The overall variability
of the pulse interval (PI) in the time domain was assessed
by the standard deviation (SD) of the time series [13,15].
Invasive Evaluation of Left Ventricular Function
One day after the final autonomic evaluation, LV function
was also measured invasively in anesthetized rats (pento-
barbital sodium, 40 mg/kg). One catheter of PE-50 was
inserted into the right carotid artery and advanced into
the LV. Ventricular pressure signals were measured with a
transducer and conditioner (Blood Pressure XDCR, Kent
©
Scientific, USA) and digitally recorded (5 min) with a data
acquisition system (WinDaq, 2-kHz, DATAQ, Springfield,
OH). The recorded data were analyzed on a beat-to-beat
basis to quantify changes in LV pressure. The following
indices were obtained: heart rate (HR), LV systolic pres-
sure (LVSP), LV end-diastolic pressure (LVEDP), and
maximum rate of LV pressure rise and fall (+dP/dt and
-dP/dt), as previously described [13,16].
Western Blot Analysis
Left ventricular homogenates were analyzed by Western
blotting to evaluate the expression of sarcoplasmic reticu-
lum calcium ATPase pump (SERCA2), phospholamban
(PLN), phosphorylated - PLN at serine 16 (phospho-ser
16-
PLN), phosphorylated - PLN at threonine 17 (phospho-
thr
17-PLN), phosphatase protein 1 (PP1), and sodium cal-
cium exchanger (NCX), as described elsewhere [17].
Mouse monoclonal antibodies to SERCA2 (1:2500), PLN
(1:500), and NCX (1:2000) were obtained from Affinity
BioReagents (Golden, CO); rabbit polyclonal antibody to
protein phosphatase type 1 (PP1, 1:1000) and protein
phosphatase type 2 A (PP2A, 1:1000) were obtained from
Upstate (Lake Placid, NY); phospho-ser
16-PLN (1:5000)
and phospho-thr
17-PLN (1:5000) were obtained from
Badrilla (Leeds, UK). Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH, 1:2000) was obtained from Advanced
Immunochemical (Long Beach, CA). Targeted bands were
normalized to cardiac GAPDH.
Statistical Analysis
Data are reported as means ± SEM. Two-way and
repeated measures ANOVA were used to compare
groups followed by the Student-Newman-Keuls post-
test. The Kaplan-Meier method was used to determine
the survival curves, which were compared by using the
log-rank test. Pearson correlation was used to study
associations between variables. Significance level was
established at p < 0.05.
Results
Animals
At the beginning of the protocol, body weight was similar
between the groups (~230 ± 15 g). After 90 days of MI,
STZ-diabetic rats had a reduced body weight (D: 213 ±
10 and DI: 211 ± 10 g) compared with normoglycemic
rats (C: 508 ± 3 and I: 471 ± 9 g). Glycemia was increased
in STZ-diabetic rats (D: 400 ± 27 and DI: 371 ± 37 mg/
dL) in comparison with normoglycemics (C: 90 ± 3 and I:
96 ± 3 mg/dL).
Left Ventricular Function: Noninvasive and Invasive
Evaluations
The myocardial infarction akinetic area (MI area) mea-
sured by echocardiography was similar between infarcted
g r o u p sa tt h ei n i t i a l( I :4 0±3a n dD I :4 1±3 %o fL V
wall) and final (I: 47 ± 2 and DI: 40 ± 4% of LV wall) eva-
luations. There was a correlation between the MI area
evaluated by echocardiography and Masson’s trichrome
stain histological method (r = 0.90, p < 0.0001).
The noninvasive left ventricular function parameters
are shown in Table 1. Initial evaluation, performed 2 days
after the myocardial infarction surgery, showed that LV
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experimental groups. In contrast, increased LV chamber
(LVEDD), reduced EF, and VCF were observed in the
infarcted groups (I and DI) compared with noninfarcted
(C and D) rats at the initial evaluation.
Final echocardiographic evaluation (90 days after myo-
cardial infarction, 105 days after STZ induction) showed
that LV mass was not different in D rats in relation to the
C; however, the I group had an increase compared with
the initial evaluation. Moreover, diastolic dysfunction was
present in D, I, and DI compared with C rats and in the
d i a b e t i cg r o u p s( Da n dD I )c o m p a r e dw i t ht h a ta tt h e
initial evaluation. The D group had reduced systolic func-
tion evaluated by EF and VCF in relation to the initial eva-
luation and C group (VCF). Myocardial infarction groups
(I and DI) demonstrated systolic dysfunction compared
with the C group. However, DI animals showed attenua-
tion of systolic dysfunction, as demonstrated by an
increase in EF and VCF compared with I rats at the final
evaluation. MPI was increased in the final evaluations of
the D, I, and DI groups in comparison with the C group.
Parallel with these results, DI had reduced MPI compared
with the I group, indicating lower global ventricular dys-
function in these animals.
Invasive LV function data, performed after the final
echocardiographic evaluation, demonstrated that the
LVSP was reduced in D, I, and DI groups compared with
that in the C group (92 ± 3, 113 ± 4, 93 ± 4 vs. 134 ±
5 mmHg, respectively). Furthermore, STZ-diabetic
animals (D and DI) had additional impairment in LVSP
compared with I animals. As expected, LVEDP was mark-
edly increased in both I (20 ± 2 mmHg) and DI (12 ±
3 mmHg) rats compared with D and C rats (6 ± 1 and 5 ±
0.3 mmHg, respectively). However, the DI group had atte-
nuated LVEDP compared with the I group. Ventricular
function was also estimated by +dP/dt (inotropic index)
and -dP/dt (lusitropic index). Experimental groups (D, I,
and DI) exhibited diastolic dysfunction evaluated by -dP/
dt compared with the C group (D: -4315 ± 473, I: -3208 ±
481, DI: -4030 ± 484 vs. C: -7186 ± 169 mmHg/sec). Simi-
larly, D, I, and DI animals displayed a reduction in +dP/dt
inotropic index (6567 ± 415, 4301 ± 457 and 5702 ±
325 mmHg/sec, respectively) compared with C animals
(9445 ± 420 mmHg/sec). However, it is important to point
out that the DI group had attenuated systolic dysfunction,
also evidenced by invasive measurements (+dP/dt), com-
pared with I rats.
Invasive LV function data paralleled echocardiography
findings, as observed by the positive correlation obtained
between LVEDD and LVEDP (r = 0.85; p < 0.0005), sug-
gesting that increased diastolic diameter was associated
with higher LVEDP values. In addition, a positive corre-
lation was also obtained between EF and +dP/dt (r =
0.82; p = 0.0007).
Hemodynamic and Autonomic Function
Hemodynamic and autonomic evaluations are presented
in Table 2. Diabetic groups (D and DI) had a reduction
Table 1 Initial and final echocardiographic measurements in control (C), diabetes (D), myocardial infarction (I), and
diabetes + myocardial infarction (DI) groups
Parameters C D I DI
Morphometric
LV mass (g/kg) Initial 1.02 ± 0.02 0.95 ± 0.01 1.05 ± 0.04 1.04 ± 0.01
Final 1.11 ± 0.03 0.95 ± 0.02 1.18 ± 0.06# 1.16 ± 0.06
LVEDD (cm) Initial 0.65 ± 0.01 0.63 ± 0.01 0.75 ± 0.01*† 0.77 ± 0.03*†
Final 0.71 ± 0.02 0.71 ± 0.02 0.85 ± 0.03*† 0.86 ± 0.03*†
Systolic
EF (%) Initial 74 ± 2 80 ± 1 48 ± 3*† 51 ± 3*†
Final 71 ± 1 61 ± 2# 42 ± 3*† 55 ± 5*‡
VCF (circ/s) (10
-4) Initial 56 ± 3 54 ± 2 38 ± 2* 38 ± 3*
Final 50 ± 3 38 ± 4#* 34 ± 2* 43 ± 1‡
Diastolic
IVRT (ms) Initial 1.81 ± 0.07 1.96 ± 0.05 1.81 ± 0.09 1.94 ± 0.08
Final 1.79 ± 0.05 2.07 ± 0.07* 2.03 ± 0.05* 2.16 ± 0.15*
EDT (ms) Initial 1.87 ± 0.11 1.95 ± 0.10 1.97 ± 0.10 1.83 ± 0.09
Final 1.75 ± 0.07 2.20 ± 0.09#* 2.13 ± 0.09* 2.45 ± 0.25#*
Global Function
MPI Initial 0.39 ± 0.01 0.41 ± 0.03 0.46 ± 0.03 0.44 ± 0.03
Final 0.34 ± 0.03 0.50 ± 0.02* 0.57 ± 0.04* 0.45 ± 0.01*‡
Values are expressed as mean ± SEM. LV mass - Left ventricular mass corrected by body weight; LVEDD - Left ventricular end-diameter during diastole; EF - Ejection
fraction; VCF - Velocity of circumferential fiber shortening; EDT- Peak E desacceleration time; IVRT- Left ventricular isovolumetric relaxation time; MPI - Myocardial
performance index. # p < 0.05 vs. initial evaluation; * p < 0.05 vs. C; † p < 0.05 vs. D; ‡ p < 0.05 vs. I (n = 8 for each group).
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compared with that in nondiabetic groups (C and I). In
addition, D, I, and DI animals had a reduction in systo-
lic arterial pressure in comparison with the C group;
however, STZ-diabetic (D and DI) rats evidenced an
additional reduction of this parameter compared to C
and I. Baroreflex sensitivity, evaluated by tachycardic
(TR) and bradycardic responses (BR), was worsened in
all experimental groups in comparison with C. There-
fore, D and DI displayed an additional reduction in BR
compared with C and I rats, as observed in the Figure 1.
Pulse interval variability, evaluated in time domain by
standard deviation of pulse interval (SD), was reduced in
all experimental animals compared with C, with addi-
tional impairment in the DI group compared with that
in D and I (Table 2).
Expression of Regulatory Proteins Involved in Intracellular
Calcium Homeostasis
GAPDH protein levels remained unchanged among all
groups studied and were used to normalize regulatory pro-
tein expression involved in calcium homeostasis. SERCA2
expression levels were reduced in both infarcted groups (I
and DI) compared with C and D (Figures 2A and 2B). In
addition, positive correlations were found between
SERCA2 and EF (r = 0.85; p < 0.001) and SERCA2 and
+dP/dt (r = 0.87; p < 0.001). NCX expression levels were
increased in D and I groups compared with C; however,
DI rats had NCX expression levels reduced in comparison
with that in D and I rats (Figures 2A and 2C). The
SERCA2/NCX ratio was reduced in D and I animals in
comparison with C, and increased in DI in comparison
with D and I animals (Figure 2D).
We additionally evaluated the expression of PLN, a
phosphoprotein that regulates the apparent calcium affi-
nity of SERCA2, and phosphorylated PLN in both Ser
16
and Thr
17 residues. PLN expression levels were increased
in group I compared with that in D, and reduced in DI
compared with that in C, D, and I groups (Figures 3A
and 3B). Additionally, the SERCA2/PLN ratio, an impor-
tant index of sarcoplasmic reticulum calcium uptake
capacity, was reduced in I animals compared with C, D,
and DI animals (Figure 3C). The expression levels of
both phospho-ser
16-PLN and phospho-thr
17-PLN were
increased only in DI animals compared with C, D, and I
rats (Figures 3A, D and 3E), indicating higher activation
of SERCA2 pump and better calcium reuptake by sarco-
plasmic reticulum in this group. PP1 expression, a PLN
phosphorylation regulator, was increased in the D group
compared with that in C; however, although the increase
Table 2 Hemodynamic measurements and pulse interval
variability in control (C), diabetes (D), myocardial
infarction (I), and diabetes + myocardial infarction (DI)
groups
Parameter/Group C D I DI
Hemodynamic
SAP (mm Hg) 129 ± 2 109 ± 3* 117 ± 3*† 106 ± 2*‡
DAP (mm Hg) 92 ± 2 83 ± 2* 90 ± 3 87 ± 2*
MAP (mm Hg) 111 ± 2 96 ± 3* 104 ± 3 99 ± 2*
HR (bpm) 352 ± 12 302 ± 7* 342 ± 6 307 ± 19*
Pulse Interval Variability
SD (bpm) 34 ± 3 22 ± 4* 24 ± 2* 13 ± 1*†‡
Values are expressed as mean ± SEM. SAP - Systolic arterial pressure; DAP -
Diastolic arterial pressure; MAP - Mean arterial pressure; HR - Heart rate; SD -
Standard deviation. * p < 0.05 vs. C; † p < 0.05 vs. D; ‡ p < 0.05 vs. I (n = 8 for
each group).
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Figure 1 Baroreflex sensitivity estimated by bradycardic (BR) and tachycardic responses (TR) from control (C), diabetes (D), myocardial
infarction (I) and diabetes + myocardial infarction (DI) rats (n = 8 for each group). * p < 0.05 vs. C; † p < 0.05 vs. D; ‡ p < 0.05 vs. I.
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were evidenced (Figures 3A and 3F).
Mortality Rate
Total mortality rate evaluation (Kaplan-Meier survival
curve) showed that groups I (13 deaths among 21 animals,
62% of mortality) and DI (22 deaths among 30 animals,
73% of mortality) had a higher mortality rate compared
with C (no deaths) and D groups (8 deaths among 16 ani-
mals, 50% of mortality). However, the DI group had an
increased mortality rate compared with I group.
Discussion
The key finding of the present study was that the ventri-
cular dysfunction determined by myocardial infarction
was attenuated in diabetic rats, an attenuation that was
associated with improved net balance of regulatory pro-
teins that participate in the cardiac calcium handling. In
opposition, autonomic dysfunction was more prominent
in DI compared with I. This alteration may have induced
an increase in the mortality rate, as observed in DI com-
pared with normoglycemic MI animals.
Epidemiological studies have shown that the incidence
of microvascular, macrovascular, and autonomic compli-
cations in diabetic patients is directly associated with the
degree of hyperglycemia [18]. Although intensive glucose
control in patients with diabetes has been acknowledged
to reduce the risk of vascular complications, the evidence
that glycemic control results in a reduction in cardiovascu-
lar disease is limited. Several prospective intervention stu-
dies published in the past 2 years have investigated
whether intensive glucose control to near-normoglycemia
reduces cardiovascular events and mortality in individuals
with diabetes and have produced conflicting results, espe-
cially with regard to risk of cardiovascular events [19-21].
In addition to the clinical studies and trials, experi-
mental designs also have reported controversial data
about the role of hyperglycemia in the mechanisms
involved in cardioprotection in animals. Several studies
have shown that hearts from diabetic rats are equally
[22] or more [5,23] sensitive to ischemic injury. In con-
trast, previous reports have demonstrated that glucose
supply plays a critical cardioprotective role in cardiac
responses during acute ischemia. These findings suggest
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Figure 2 Expression levels of regulatory proteins related to intracellular calcium homeostasis from control (C), diabetes (D),
myocardial infarction (I), and diabetes + myocardial infarction (DI) rats (n = 8 for each group). Targeted bands were normalized to
cardiac GAPDH. A) Representative blots of SERCA2, Na
+-Ca
2+ exchanger (NCX) and GAPDH; B) SERCA2; C) NCX; and D) SERCA2/NCX ratio. * p <
0.05 vs. C; † p < 0.05 vs. D; ‡ p < 0.05 vs. I.
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Figure 3 Expression levels of intracellular calcium efflux mediators from control (C), diabetes (D), myocardial infarction (I), and
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tolerance to ischemic stress, leading to changes in sig-
naling mechanisms involved in cardioprotection [24,25].
Recently, Chu et al. [8] provided evidence that diabetes
induced by Aloxan and resultant hyperglycemia, though
detrimental to global cardiac function and associated
with a poorer prognosis, was cardioprotective against
myocardial ischemic-reperfusion injury in pigs in the
short-term. The authors observed a pronounced reduc-
tion in the myocardial infarction area in diabetic ani-
mals, likely being a result of increased availability and
use of glucose, the heart’s preferred energy substrate in
times of stress.
In fact, some studies have demonstrated that the
reduction in myocardial infarction size [26] is deter-
mined by the diminished number of dead myocytes in
diabetic animals [27], and would be the key point to the
higher resistance of diabetic rats to ischemic injury. In
contrast with the results in the literature and data from
our group [9], the MI area was similar between I and DI
groups in the present study. This discrepancy in data
may be the result of the prolonged time of diabetes and
MI investigated here. Thus, the higher resistance of the
diabetic heart cannot be explained by the reduction in
the myocardial infarction akinetic area in the present
study.
Morphological and Functional Responses to Ischemic
Injury
Myocardial remodeling after MI is usually characterized
by compensatory hypertrophy of myocytes, ventricular
dilatation and increased interstitial collagen deposition
and fibrosis [5]. In our study, LVEDD was increased in
infarcted compared with noninfarcted groups; however I
and DI groups had similar results of LV mass and
LVEDD, highlighting the fact that STZ-diabetes had no
influence on cardiac remodeling after MI. To the con-
trary, Bäcklund et al. [5] showed that 12 weeks after MI
surgery cardiomyocyte apoptosis was associated with LV
enlargement and increased cardiac fibrosis in diabetic
animals. However, it is possible that the prolonged time
of STZ-diabetes (4 weeks) before the MI surgery, in
contrast with our study (15 days), has been the responsi-
ble for discrepancy in the results.
To further investigate the mechanisms underlying the
improved tolerance to ischemia of diabetic rats, we eval-
uated the cardiac function of the experimental groups.
Our data indicate that diabetes partially attenuated the
ventricular dysfunction caused by myocardial ischemia
(DI animals compared with I animals). In fact, DI ani-
mals had improved systolic and diastolic function
indexes, paralleled by reduced MPI, an index that repre-
sents global myocardial stress [16]. These data corrobo-
rate previous findings of our group where 15 days after
MI, STZ-diabetic rats had attenuation of cardiac dys-
function compared with the normoglycemic rats. Inter-
estingly, this attenuation was associated with an
improved net balance of inflammatory cytokines and
regulatory genes that participate in cardiac cellular
survival [9].
Molecular Changes
Because cardiac dysfunction observed in cardiomyopathy
and heart failure is strongly associated with the expres-
sion profile of the cardiac proteins related to intracellular
calcium handling [11], we evaluated the SERCA2, PLN,
phospho-ser
16-PLN, phospho-thr
17-PLN, PP1, and NCX.
It was previously reported that in heart failure cardiac
dysfunction is in part a consequence of changes in intra-
cellular calcium homeostasis, which may be related to an
altered expression, function, or regulation of SERCA2
[11,28]. In the present study, although the MI groups
(I and DI) displayed a reduction in SERCA2 expression,
the DI group had a decrease in NCX and PLN proteins,
resulting in increased SERCA2/NCX and SERCA2/PLN
ratios in comparison with those in the I group. This find-
ing may indicate a relative increase in SERCA2 pump
function and increased available calcium in the cytoplasm
in diabetic animals that undergo MI, if compared with
normoglycemic MI rats. Likewise, increased phosphoryla-
tion of PLN in both serine
16 and threonine
17 in DI rats
reinforces the possibility that SERCA2 function is better
preserved in these experimental animals. Indeed, the
phosphorylation of PLN in both residues is involved in
an increased calcium reuptake by sarcoplasmic reticulum,
although the increase in PLN phosphorylation at Thr
17
m a yb ei n t e r p r e t e d ,i ns o m ec a s e s ,a so n eo ft h el a t e s t
compensatory mechanisms activated when cardiac func-
tion is deteriorated, as observed in acidosis and reperfu-
sion periods [29].
In the present study, because the molecular analyses
were performed in all LV homogenates to quantify the
expression of proteins by Western blot, it is possible that
the compensatory mechanisms involving calcium regula-
tion in the noninfarcted area might have influenced the
results. However, it is necessary to consider that not only
the myocardial infarction area, but also LV mass were
similar between the infarcted groups (I and DI). These
findings suggest that experime n t a ld i a b e t e si sa s s o c i a t e d
with the activation of endogenous cardioprotective
mechanisms, which successfully remain after 90 days of
myocardial ischemia attenuating the remaining LV dys-
function in the DI group.
Autonomic Impairment and Mortality Rate
Independently of the mechanism involved in the pre-
served left ventricular function observed in DI rats, it
was expected that the mortality rate would be reduced
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animals evidenced an increase in mortality rate 90 days
after myocardial infarction compared with the I group,
suggesting that other mechanisms and dysfunctions
might be influencing the survival rate of the diabetic
animals. Possible mechanisms, all involving the meta-
bolic characteristic of the diabetic state, have been pre-
viously suggested: long duration of the diabetes, severity
of hyperglycemia [30], high levels of circulating free
fatty acids, and decreased glucose utilization by cardio-
myocytes [31] which contribute to contractile derange-
ment [32] and higher arrhythmia susceptibility [33]. In
fact, van den Brom et al., [34], by using positron emis-
sion tomography and echocardiography, evidenced
increases in myocardial fatty acid oxidation with a con-
comitant decrease of insulin-mediated myocardial glu-
cose utilization in early diabetic cardiomyopathy. In
addition, the authors observed that these metabolic
alterations were associated with impaired myocardial
function.
Cardiovascular autonomic neuropathy has been consid-
ered an important determinant of mortality in diabetic
patients independently of other known risk factors [35].
In the present study, more prominent autonomic dys-
function was observed in the DI group compared with
that in I animals. This evidence may indicate that auto-
nomic dysfunction, previously described by us [36,37],
could be influencing the mortality observed in D and
mainly in DI rats. In accordance with these results, our
group previously demonstrated that sedentary STZ dia-
betic rats had accentuated autonomic dysfunction and
c o n s e q u e n t l yah i g h e rm o r t a l i t yr a t e( ~ 4 9 % )c o m p a r e d
with control rats. Additionally, 8 weeks of aerobic exer-
cise training attenuated the autonomic dysfunction and
reduced the mortality levels in the trained group to 16%
[36]. For this reason, new therapeutic strategies have
been studied in diabetes management. Shyu et al., [38]
described the isolation of pancreatic endocrine precursor
cells, from adult human pancreatic tissue, and the redif-
ferentiation of insulin-secreting b-like cells from in vitro-
cultured insulin-producing cell precursors. These data
emphasize that surgically resected pancreatic tissue may
represent an alternative source of functional insulin-
producing cells and to minimize the cardiovascular
dysfunctions of diabetes.
Study Limitations
Some possible limitations of the present investigation
deserve comment. First, because the MI animals (I and
DI) started the protocol with similar values for MI area
and LF function and necropsy evaluations were not per-
formed in the animals that died during the 90 days of
the protocol, the prediction of survival (or mortality)
based on these parameters becomes difficult and is lim-
ited to methods used in this study. Second, the hemody-
namic and autonomic parameters were evaluated at the
end of the protocol, and comparisons were made by
including a control group in the experimental design.
Indeed, the direct method for recording blood pressure
depends on the catheterization of arterial vessels that
are functional during a small time period. Consequently,
the biological signals were recorded only at the end of
the experimental period, leading to the lack of baseline
values in the same animals at the start of the study.
Conclusion
We have demonstrated that the left ventricular dysfunc-
tion in diabetic animals was attenuated after 90 days of
myocardial infarction. This is probably a compensatory
mechanism associated with metabolic and molecular
adjustments of the cardiac tissue, where the end point
was a better profile of calcium handling proteins. How-
ever, this positive adaptation was not able to reduce the
mortality rate of DI animals. These data suggest that
other mechanisms, as well as cardiovascular autonomic
dysfunction identified in this study, is associated with
mortality rate in these animals. It is important to empha-
size that in the present investigation, the time course of
diabetes and MI was determined and well knows, in con-
trast with that observed in clinical situations. Therefore,
it is possible that the better cardiac function has been
transitory in DI rats, and the autonomic dysfunction,
more prominent in diabetics, may lead, in the future, to
cardiovascular damage, as observed in diabetic patients
after an ischemic event.
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